🇺🇸 FDA
Pipeline program

Xingnaojing injection

2014BAI10B05-01

Approved small_molecule active

Quick answer

Xingnaojing injection for Acute Ischemic Stroke is a Approved program (small_molecule) at China SXT Pharmaceuticals with 1 ClinicalTrials.gov record(s).

Program details

Company
China SXT Pharmaceuticals
Indication
Acute Ischemic Stroke
Phase
Approved
Modality
small_molecule
Status
active

Clinical trials